131 related articles for article (PubMed ID: 23542073)
1. Trojan horse at cellular level for tumor gene therapies.
Collet G; Grillon C; Nadim M; Kieda C
Gene; 2013 Aug; 525(2):208-16. PubMed ID: 23542073
[TBL] [Abstract][Full Text] [Related]
2. Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene.
Cao X; Yang M; Wei RC; Zeng Y; Gu JF; Huang WD; Yang DQ; Li HL; Ding M; Wei N; Zhang KJ; Xu B; Liu XR; Qian QJ; Liu XY
Gene Ther; 2011 Aug; 18(8):765-77. PubMed ID: 21412282
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in delivery of drug-nucleic acid combinations for cancer treatment.
Li J; Wang Y; Zhu Y; Oupický D
J Control Release; 2013 Dec; 172(2):589-600. PubMed ID: 23624358
[TBL] [Abstract][Full Text] [Related]
4. Mesenchymal stem cells as a novel carrier for targeted delivery of gene in cancer therapy based on nonviral transfection.
Hu YL; Huang B; Zhang TY; Miao PH; Tang GP; Tabata Y; Gao JQ
Mol Pharm; 2012 Sep; 9(9):2698-709. PubMed ID: 22862421
[TBL] [Abstract][Full Text] [Related]
5. Long-circulating liposome-encapsulated ganciclovir enhances the efficacy of HSV-TK suicide gene therapy.
Kajiwara E; Kawano K; Hattori Y; Fukushima M; Hayashi K; Maitani Y
J Control Release; 2007 Jul; 120(1-2):104-10. PubMed ID: 17509714
[TBL] [Abstract][Full Text] [Related]
6. Differential chemosensitivity of breast cancer cells to ganciclovir treatment following adenovirus-mediated herpes simplex virus thymidine kinase gene transfer.
Li PX; Ngo D; Brade AM; Klamut HJ
Cancer Gene Ther; 1999; 6(2):179-90. PubMed ID: 10195885
[TBL] [Abstract][Full Text] [Related]
7. The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity.
Wildner O; Morris JC
Cancer Res; 2000 Aug; 60(15):4167-74. PubMed ID: 10945625
[TBL] [Abstract][Full Text] [Related]
8. Cancer-specific targeting of an adenovirus-delivered herpes simplex virus thymidine kinase suicide gene using translational control.
Mathis JM; Williams BJ; Sibley DA; Carroll JL; Li J; Odaka Y; Barlow S; Nathan CO; Li BD; DeBenedetti A
J Gene Med; 2006 Sep; 8(9):1105-20. PubMed ID: 16802401
[TBL] [Abstract][Full Text] [Related]
9. Co-expression of herpes simplex virus thymidine kinase and Escherichia coli nitroreductase by an hTERT-driven adenovirus vector in breast cancer cells results in additive anti-tumor effects.
Yu B; Zhang Y; Zhan Y; Zha X; Wu Y; Zhang X; Dong Q; Kong W; Yu X
Oncol Rep; 2011 Jul; 26(1):255-64. PubMed ID: 21573500
[TBL] [Abstract][Full Text] [Related]
10. A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer.
Hall SJ; Canfield SE; Yan Y; Hassen W; Selleck WA; Chen SH
Gene Ther; 2002 Apr; 9(8):511-7. PubMed ID: 11948376
[TBL] [Abstract][Full Text] [Related]
11. Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing.
Wiewrodt R; Amin K; Kiefer M; Jovanovic VP; Kapoor V; Force S; Chang M; Lanuti M; Black ME; Kaiser LR; Albelda SM
Cancer Gene Ther; 2003 May; 10(5):353-64. PubMed ID: 12719705
[TBL] [Abstract][Full Text] [Related]
12. Adeno-associated viral-mediated gene transfer to hepatoma: thymidine kinase/interleukin 2 is more effective in tumor killing in non-ganciclovir (GCV)-treated than in GCV-treated animals.
Su H; Lu R; Ding R; Kan YW
Mol Ther; 2000 Jun; 1(6):509-15. PubMed ID: 10933975
[TBL] [Abstract][Full Text] [Related]
13. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.
Höbel S; Koburger I; John M; Czubayko F; Hadwiger P; Vornlocher HP; Aigner A
J Gene Med; 2010 Mar; 12(3):287-300. PubMed ID: 20052738
[TBL] [Abstract][Full Text] [Related]
14. Strategy of Cancer Targeting Gene-Viro-Therapy (CTGVT) a trend in both cancer gene therapy and cancer virotherapy.
Liu XY; Li HG; Zhang KJ; Gu JF
Curr Pharm Biotechnol; 2012 Jul; 13(9):1761-7. PubMed ID: 21740358
[TBL] [Abstract][Full Text] [Related]
15. Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus.
Raki M; Hakkarainen T; Bauerschmitz GJ; Särkioja M; Desmond RA; Kanerva A; Hemminki A
Gene Ther; 2007 Oct; 14(19):1380-8. PubMed ID: 17611584
[TBL] [Abstract][Full Text] [Related]
16. Endothelial progenitor cells as cellular vehicles to deliver oncolytic virus therapies to metastatic tumors: the "Trojan horse" approach.
Deng W; Jia J
Med Hypotheses; 2008; 70(4):842-4. PubMed ID: 17869010
[TBL] [Abstract][Full Text] [Related]
17. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies.
Aghi M; Chou TC; Suling K; Breakefield XO; Chiocca EA
Cancer Res; 1999 Aug; 59(16):3861-5. PubMed ID: 10463570
[TBL] [Abstract][Full Text] [Related]
18. Retrovirus-mediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ganciclovir paradigm.
Rainov NG; Kramm CM; Aboody-Guterman K; Chase M; Ueki K; Louis DN; Harsh GR; Chiocca A; Breakefield XO
Cancer Gene Ther; 1996; 3(2):99-106. PubMed ID: 8729908
[TBL] [Abstract][Full Text] [Related]
19. Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer.
Hall SJ; Mutchnik SE; Yang G; Timme TL; Nasu Y; Bangma CH; Woo SL; Shaker M; Thompson TC
Cancer Gene Ther; 1999; 6(1):54-63. PubMed ID: 10078964
[TBL] [Abstract][Full Text] [Related]
20. Non-small cell lung cancer as a target disease for herpes simplex type 1 thymidine kinase-ganciclovir gene therapy.
Määttä AM; Tenhunen A; Pasanen T; Meriläinen O; Pellinen R; Mäkinen K; Alhava E; Wahlfors J
Int J Oncol; 2004 Apr; 24(4):943-9. PubMed ID: 15010834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
